EMEA-000118-PIP04-17
Key facts
| Invented name |
Orencia
|
| Active substance |
Abatacept
|
| Therapeutic area |
Immunology-Rheumatology-Transplantation
|
| Decision number |
P/0183/2018
|
| PIP number |
EMEA-000118-PIP04-17
|
| Pharmaceutical form(s) |
|
| Condition(s) / indication(s) |
|
| Route(s) of administration |
|
| Contact for public enquiries |
Bristol-Myers Squibb Pharma EEIG
E-mail: medical.information@bms.com |
| Decision type |
W: decision granting a waiver in all age groups for all conditions or indications
|